← Back to screener

Chemomab Therapeutics Ltd. CMMB

Rank #2339 · Nasdaq · $0.7B market cap
Audited by Somekh Chaikin, no going-concern flag in the latest filing.
Score
23.6
P/E
-53.5
P/B
61.79
ROE
-115.5%
Op. Margin
–%
Debt Ratio
27%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -53.5x, P/B 61.79x. Ranks in the top 82% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -115.5%. Ranks in the top 95% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 27%. Ranks in the top 16% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2019––$-0.0B$-0.0B–-485
2020––$-0.0B$0.0B–49
2021––$-0.0B$0.0B–14
2022––$-0.0B$0.0B–27

← See the full screener